Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01011517 · ClinicalTrials.gov registry record · NA

Muscadine Grape Seed Supplementation and Vascular Function

A NA study, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
NA
Development phase
50
Enrollment target

NCT01011517 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 50 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01011517, a NA study, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target

Study Summary

The investigators sought to evaluate the effect of muscadine grape seed supplementation on brachial diameter and flow-mediated vasodilator responses in subjects with, or at risk for cardiovascular disease. Methods: In a randomized, double-blind, placebo-controlled crossover trial, 50 adults (25 men, 25 women) with one or more cardiac risk factors were randomized to muscadine grape seed (MGS) supplement 1300mg daily vs.. placebo for 4 weeks each, with a 4-week washout between study periods. Resting diameter and endothelial function measured using brachial flow-mediated dilation (FMD) were determined at the beginning and end of each study period.

Interventions

  • DIETARY_SUPPLEMENT Muscadine grape seed supplement

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2007-06
Est. Completion 2008-09
Phase NA

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT01011517

The ClinicalTrials.gov registry entry for NCT01011517 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Muscadine grape seed supplement is the first listed.

NCT01011517 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01011517 about?

NCT01011517 is a clinical study titled "Muscadine Grape Seed Supplementation and Vascular Function". The investigators sought to evaluate the effect of muscadine grape seed supplementation on brachial diameter and flow-mediated vasodilator responses in subjects with, or at risk for cardiovascular disease. Methods: In a randomized, double-blind, placebo-controlled crossover trial, 50 adults (25 men...

What is the current status of trial NCT01011517?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2007-06. Estimated completion is 2008-09.

What interventions are being tested in trial NCT01011517?

The interventions under investigation include: Muscadine grape seed supplement (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01011517?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.